Answers are grounded in this paper and cite their sources.
Karyotype analysis is the gold standard of care for evaluating patients suspected of having mosaicism involving sex chromosomes or autosomes. Accurately determining the level of mosaicism is important, as it can vary widely and may be linked to disease severity. However, current guidelines do not clearly specify how many cells should be examined in order to exclude low‐level mosaicism. In our retrospective study of cytogenetic results from 113 specimens, each with a minimum of 100 cells examined, we assessed whether the extensive analysis provided additional clinical value. Common indications for cytogenetic testing in these cases include Turner syndrome, premature ovarian failure, Klinefelter syndrome, infertility, and multiple miscarriages. In 83% (94/113) of cases, additional cells were examined because initial analysis suggested low‐level mosaicism; however, further analysis did not confirm the initial findings in 66 of these 94 cases, indicating they were likely artifacts. Notably, none of the seven repeated analyses of 100 or 200 cells corroborated previous reports of low‐level or clinically suspected mosaicism. Examination of additional cells confirmed the presence of a second cell line at low level in 25% (28/113) of cases, most often associated with X chromosome aneuploidies in adult females, likely age‐related and without clear clinical significance. These results suggest that case‐by‐case consideration is still important, but no clinically significant findings resulted from analyzing more than 40 cells, indicating that extensive additional cell analysis is generally unnecessary for ruling out low‐level mosaicism in clinical cytogenetic practice.
No takes yet. Share an insight, caveat, or question.
Iwata‐Otsubo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: